Sydney - Wednesday - Sep 27: (RWE Australian Business News)...

Sydney - Wednesday - Sep 27: (RWE Australian Business News) -
Australian biotechnology company Peptech Ltd (ASX: PTD) today announced
it had passed a critical milestone on its path to commercialisation of
the potential blockbuster drug, PN0621, by acknowledging the receipt of
a substantial amount of the anti-TNF domain antibody (dAb)-based
compound produced to the standards of Good Manufacturing Practice (GMP).
Peptech has received sufficient quantity of clinical grade
PN0621 to advance further preclinical safety assessments and enable
completion of Phase I and subsequently, Phase II human clinical
trials.
The compound, to be trialled in multiple inflammatory diseases,
has been produced to the exacting standards of GMP at industry-leading
levels by an internationally reputed biopharmaceutical manufacturer.
Levels of production and yield of purified material continue to
exceed expectations.